Abbas HA, Wierda WG. Acalabrutinib: A selective Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol 2021;11:668162. Abstract
Cherng H-JJ et al. Retrospective single-institution analysis of patients with chronic lymphocytic leukemia with TP53 alterations treated first-line with Bruton’s tyrosine kinase inhibitor-based therapy. ASH 2021;Abstract 394.
De Novellis D et al. The TKI era in chronic leukemias. Pharmaceutics 2021;13(12):2201. Abstract
Ghia P et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. ASCO 2021;Abstract 7501.
Jain N et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: A nonrandomized phase 2 trial. JAMA Oncol 2021;7(8):1213-19. Abstract
Jain N et al. Venetoclax, obinutuzumab and atezolizumab (PD-L1 checkpoint inhibitor) for first-line treatment for patients with chronic lymphocytic leukemia (CLL). ASH 2021;Abstract 2626.
Kantarjian HM et al. The cure of leukemia through the optimist’s prism. Cancer 2022;128(2):240-59. Abstract
Mato AR et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet 2021;397(10277):892-901. Abstract
Mato AR et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. ASH 2021;Abstract 391.
O’Brien SM et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol 2021;11:720704. Abstract
Siddiqi T et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2021;[Online ahead of print]. Abstract
Sivina M et al. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations. Blood 2021;138(24):2589-92. Abstract
Tambaro FP et al. The role of BTK inhibition in the treatment of chronic lymphocytic leukemia: A clinical view. J Exp Pharmacol 2021;13:923-35. Abstract
Wierda WG et al. Measurable residual disease in chronic lymphocytic leukemia: Expert review and consensus recommendations. Leukemia 2021;35(11):3059-72. Abstract